- Home
- SHMD vs QNCX Comparison
SHMD vs QNCX Comparison
Compare SHMD & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | QNCX |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.8M | 17.5M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHMD | QNCX |
|---|---|---|
| Price | $3.00 | $32.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 552.9K | 28.6K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.08 |
| 52 Week High | $10.65 | $35.41 |
Technical Indicators
Market Signals| Indicator | SHMD | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 62.71 |
| Support Level | N/A | $0.82 |
| Resistance Level | $5.63 | $35.41 |
| Average True Range (ATR) | 0.45 | 2.37 |
| MACD | -0.16 | -0.68 |
| Stochastic Oscillator | 5.81 | 43.02 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.